GlassScriptPhysician profile
Horacio A Hidalgo
NPI 1356309462
$11,085.77
in general payments reported to CMS, 2019-2025
42 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,300 · 2020: $1,521 · 2021: $1,243 · 2022: $1,241 · 2023: $1,694 · 2024: $1,749 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,477.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,301.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,038.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $823.15 | 2019-2024 | |
| Lilly USA, LLC | $759.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $725.54 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $458.99 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $435.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $433.55 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.10 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $339.82 | 2020-2024 | |
| Glaxosmithkline, LLC. | $299.70 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $295.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.62 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $281.66 | 2019-2025 | Spravato |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horacio Hidalgo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.